Ecklonia cava Ecklonia cava Kjellman, 1885 (marine brown alga; accepted name in WoRMS)
Also called: Ecklonia cava phlorotannins, dieckol-rich extract, brown algae polyphenols
Ecklonia cava is an edible brown seaweed of southern Japan and South Korea. Supplements use alcohol extracts rich in phlorotannins such as dieckol; in the EU, Ecklonia cava phlorotannins are an authorized novel food. Human trials are small and short.
- Category
- Marine and algae
- Forms
- Alcohol extract of the dried seaweed (phlorotannin-rich)
- Strongest evidence
- C Limited
- Native range
- Edible marine brown alga (family Lessoniaceae in WoRMS), abundant in southern Japan and South Korea (EFSA 2017)
- Reviewed
- 2026-10-29
Class 2 Moderately studied in people. This entry cites 4 RCTs of Ecklonia cava extract alone (sources [3], [4], [5], [7]), 12 to 97 participants. The 2018 review (source [6]) pooled polyphenols from several seaweeds, not E. cava alone. [3]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CHeart and blood vessels2 topics
CBlood sugar and weight2 topics
CMuscles and exercise1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Post-meal blood glucose in prediabetes (12 weeks) | C | In an RCT of 80 prediabetic adults, a dieckol-rich extract (1,500 mg/day for 12 weeks) lowered postprandial glucose versus placebo; insulin and C-peptide did not differ significantly from placebo. [3] |
| Post-meal blood glucose in prediabetes (single dose) | C | In an RCT in 20 prediabetic adults, a single 600 mg dose lowered glucose at 90 and 120 minutes after a 75 g carbohydrate load, but glucose area under the curve and insulin did not differ. [4] |
| Body fat and blood lipids in overweight adults | C | In a 12-week RCT of 97 overweight Korean adults, 72 or 144 mg/day polyphenol extract lowered BMI, body fat, waist size, total and LDL cholesterol versus placebo. [5] |
| Glucose and lipids across marine algal polyphenol trials | C | A 2018 systematic review of five trials (271 adults) found small-to-medium effects on fasting glucose, total and LDL cholesterol, but inadequate evidence to confirm consistent effects. [6] |
| Cycling and sprint performance (single dose) | C | In a crossover RCT in 12 trained male cyclists, 263 mg extract before exercise did not improve sprint power or other measured responses; blood glucose was slightly higher overall. [7] |
Main constituents: Phlorotannins (polyphenols): 90 ± 5% of the EU novel-food extract by Folin-Ciocalteu, including dieckol (6.6-9.9% by HPLC), 8,8'-bieckol, 6,6'-bieckol, eckol and phlorofucofuroeckol-A [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- 1,500 mg/day dieckol-rich extract for 12 weeks (prediabetes RCT). [3]
- 72 mg/day or 144 mg/day polyphenol extract for 12 weeks (overweight adults RCT). [5]
- A single 600 mg dose before a 75 g carbohydrate load (glucose study). [4]
- A single 263 mg dose 30 minutes before exercise (cycling study). [7]
Upper limits
- EFSA (2017) concluded the EU novel-food extract is safe in food supplements at up to 263 mg/day for adults, 230 mg/day for adolescents over 14 and 163 mg/day for adolescents aged 12-14. [1]
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notifications3 on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- EFSA notes that iodine intake from the extract may be of concern for people at risk of thyroid disease, and that adding other iodine-containing supplements might push iodine intake above the upper level. [1]
- EU Member States commenting on the application raised concern that the arsenic level of the extract may pose a safety concern with long-term use (specification: arsenic below 25 mg/kg). [1]
- No significant adverse events related to the extract were reported in the 12-week prediabetes trial; blood chemistry and hematology stayed within normal ranges. [3]
Interactions
| With | What happens |
|---|---|
| Other iodine-containing supplements | EFSA notes that combining them with the extract might lead to iodine intakes above the upper level. [1] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Identity, quality and standardization
- EFSA specification for the novel food includes iodine 150-650 mg/kg, arsenic below 25 mg/kg, lead below 3 mg/kg, cadmium below 3 mg/kg and mercury below 0.1 mg/kg. [1]
- EU Member States noted that the Folin-Ciocalteu method used to quantify phlorotannins is prone to erroneous values, and raised concern about a significant proportion of not fully characterized phlorotannins. [1]
Regulatory status
- EU: Ecklonia cava phlorotannins were authorized as a novel food by Commission Implementing Regulation (EU) 2018/460 of 20 March 2018. [2]
- US: FDA's published NDI notification list has 3 entries naming Ecklonia cava (earliest NDI 419 submitted 2006-09-13; most recent NDI 1288 submitted 2023-04-04). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [9]
- US: FDA states that, by law, it does not approve dietary supplements or their labeling before they are marketed; firms are responsible for the safety and labeling of their products. [10]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
US status
What FDA's published records show. FDA does not approve dietary supplements.
- FDA's published NDI notification list has 3 entries naming Ecklonia cava (earliest NDI 419 submitted 2006-09-13; most recent NDI 1288 submitted 2023-04-04). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- Other iodine-containing supplements: EFSA notes that taking them with the extract might lead to iodine intakes above the upper level. [P1]
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test of the dietary ingredient (at least one appropriate test or examination before use) — 21 CFR 111.75(a)(1)(i) requires identity verification of every component that is a dietary ingredient, unless FDA exempts the firm on petition under 111.75(a)(1)(ii). [P5]
- Phlorotannin and dieckol content (EFSA specification: phlorotannins 90 ± 5%, dieckol 6.6-9.9% by HPLC) — Defines the authorized EU novel food; the Folin-Ciocalteu assay was criticized as prone to erroneous values. [P1]
- Iodine (specification 150-650 mg/kg) — EFSA flagged iodine intake as a possible concern for people at risk of thyroid disease. [P1]
- Arsenic, lead, cadmium and mercury — EU Member States raised concern about the arsenic level; the specification sets As below 25, Pb below 3, Cd below 3 and Hg below 0.1 mg/kg. [P1]
- Pesticide residues — Traces of azinphos-methyl and phenthoate were detected in samples during the EU assessment, and the applicant changed harvest location. [P1]
Supply and conservation
- EFSA: Ecklonia cava is abundant in southern Japan and South Korea; the seaweed for the EU novel food is sourced from Jeju Island, South Korea. [P1]
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- EFSA NDA Panel. Safety of Ecklonia cava phlorotannins as a novel food pursuant to Regulation (EC) No 258/97. EFSA J 2017;15(10):5003 (PMID 32625298; full text PMC7010033), 2017-10-16. pmc.ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. Agents classified by the IARC Monographs (list of classifications, checked 2026-10-29), 2026-10-29. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (list checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75 (current as of October 27, 2026), 2026-10-27. ecfr.gov
Sources
- EFSA NDA Panel. Safety of Ecklonia cava phlorotannins as a novel food pursuant to Regulation (EC) No 258/97. EFSA J 2017;15(10):5003 (PMID 32625298; full text PMC7010033), 2017-10-16. pmc.ncbi.nlm.nih.gov
- Commission Implementing Regulation (EU) 2018/460 of 20 March 2018 authorising the placing on the market of Ecklonia cava phlorotannins as a novel food (EUR-Lex), 2018-03-20. eur-lex.europa.eu
- Lee SH, Jeon YJ. Efficacy and safety of a dieckol-rich extract (AG-dieckol) of brown algae, Ecklonia cava, in pre-diabetic individuals: a double-blind, randomized, placebo-controlled clinical trial. Food Funct 2015;6(3):853-8 (PMID 25608849), 2015-03. pubmed.ncbi.nlm.nih.gov
- Almutairi MG, et al. Effect of seaweed (Ecklonia cava extract) on blood glucose and insulin level on prediabetic patients: a double-blind randomized controlled trial. Food Sci Nutr 2023;11(2):983-990 (PMID 36789057), 2022-12-07. pubmed.ncbi.nlm.nih.gov
- Shin HC, et al. Effects of 12-week oral supplementation of Ecklonia cava polyphenols on anthropometric and blood lipid parameters in overweight Korean individuals: a double-blind randomized clinical trial. Phytother Res 2012;26(3):363-8 (PMID 21717516), 2012-03. pubmed.ncbi.nlm.nih.gov
- Murray M, et al. Do marine algal polyphenols have antidiabetic, antihyperlipidemic or anti-inflammatory effects in humans? A systematic review. Crit Rev Food Sci Nutr 2018;58(12):2039-2054 (PMID 28414549), 2017-07-05. pubmed.ncbi.nlm.nih.gov
- Ali Y, et al. Effects of acute Ecklonia cava supplementation on submaximal cycling and repeated-sprint performance in trained cyclists: a randomised double-blind placebo-controlled crossover trial. Nutrients 2026;18(20):3430 (PMID 42943001), 2026-10-19. pubmed.ncbi.nlm.nih.gov
- WoRMS (World Register of Marine Species). Ecklonia cava Kjellman, 1885, AphiaID 371986 (accessed 2026-10-29; basis of record AlgaeBase), 2026-10-29. marinespecies.org
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in marine and algae: Astaxanthin · Bladderwrack · Carrageenan and agar · Chlorella · Dunaliella · Fucoidan · Kelp and seaweed · Sea moss · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.